Drug intelligence / Profile preview

WG104

Development stage: Unknown
Lead developer: Shenzhen Wingor Biotechnology
Modality: Stem Cell Therapies → Cell Therapies

Overview

WG104 is an investigational stem cell therapy developed by Shenzhen Wingor Biotechnology. It is part of the company's pipeline of stem cell-based drug candidates designed to address unmet needs in immune-mediated, chronic, and degenerative diseases. WG104 has reached a significant regulatory milestone with its Investigational New Drug (IND) application being accepted by the National Medical Products Administration (NMPA) in China. The therapy aims to leverage the regenerative and immunomodulatory properties of stem cells to provide therapeutic benefits for conditions including rare diseases and oncology.

Beyond the preview

Go deeper on WG104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WG104.

Explore the full profile